9 Investigator Site Networks Operating in the United Kingdom in 2026

A clinical investigator site network is where a trial actually happens: the physical location, staff, and principal investigator responsible for enrolling and treating patients according to protocol. The UK's site landscape spans purpose-built early-phase pharmacology units attached to teaching hospitals, specialist facilities built for a single research modality such as human challenge trials or psychedelic-assisted therapy, and pan-European site networks with UK headquarters.

The investigator site networks below are listed in no particular order and are all headquartered in the United Kingdom. Between them, these companies and providers cover Phase 1 pharmacology units, neuroscience and memory-focused site networks, gene-editing and human challenge trial specialists, and technology-driven CRO platforms with their own site capabilities.

BDD Pharma

BDD Pharma combines early-phase formulation development with in-house Phase 1 clinical testing at its Glasgow, Scotland facilities, built around a patented, pH-independent timed drug-release technology called OralogiK. The company traces its origins to spin-out work from the University of Strathclyde and marked its 25th anniversary in 2025, having grown from a small formulation lab into a combined CDMO and CRO with its own clinical site at Glasgow Royal Infirmary. In late 2024, BDD ran a Phase 1b trial for Contera Pharma testing a delayed-release levodopa/carbidopa formulation in Parkinson's disease patients, using its on-site gamma camera imaging to track drug release timing. CEO Dr. Carol Thomson has said BDD's integrated Lean Clinical Development approach removes the need to outsource formulation scale-up, keeping the process in-house from concept through Phase 1 execution.

Clerkenwell Health

Clerkenwell Health operates what it describes as Europe's first commercial facility dedicated to psychedelic-assisted clinical trials, a purpose-built site near Harley Street in central London. Founded in 2020 and led by CEO Tom McDonald, the company raised £2.1 million in seed funding to get the site operational and has run trials for drug developers including Psyence, Mindset, PharmAla, and Mydecine, testing compounds such as psilocybin and 5-MeO-DMT for conditions including treatment-resistant depression and end-of-life anxiety in cancer patients. Clerkenwell Health also trains the specialized therapists required to deliver psychedelic-assisted therapy sessions alongside its trial delivery services. The company has partnered with organizations including Beckley Psytech and pre-clinical CRO Transpharmation to combine laboratory and human trial work on the same compounds.

FutureMeds

FutureMeds operates what it calls the first Dedicated Clinical Trial (DCT) site network in Europe, running more than 27 wholly owned research sites across 7 countries alongside a network of over 1,400 homecare providers who can deliver trial visits directly to participants' homes. Founded in 2020 by CEO Dr. Radoslaw Janiak and headquartered in Liverpool, England, the company reported a 280 percent revenue increase in 2022 as it expanded its site footprint across Poland, Germany, Spain, and Ukraine. FutureMeds acquired emovis, a Berlin-based homecare visits provider with more than 11 years of decentralized trial experience, in 2023, adding an award-winning Homecare Visits service used in 16 European countries to its network. Janiak was named a regional finalist in the EY Entrepreneur Of The Year UK program.

hVIVO

hVIVO, formerly known as Open Orphan, is the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, where healthy volunteers are deliberately exposed to a pathogen under controlled conditions. The company ran the world's first human challenge trial for COVID-19 in 2021, working with Imperial College London and the Royal Free London NHS Foundation Trust to establish the minimal viral dose needed to cause infection in young, healthy adults. hVIVO operates a portfolio of 11 human challenge models from clinics in East London, including its Whitechapel quarantine facility, and has run studies involving roughly 3,000 volunteers across 56 respiratory virus challenge trials to date. The publicly traded company (ticker: HVO) serves a client base that includes four of the world's ten largest biopharma companies.

Lindus Health

Lindus Health positions itself as an "anti-CRO," an end-to-end clinical trial execution platform built on a proprietary AI system called Citrus that the company says can run trials up to three times faster than traditional providers. Founded in March 2021 by Michael Young, a former Special Adviser to the UK Prime Minister on Life Sciences, alongside Meri Beckwith and Nik Haldimann, the London and New York-based company closed a $55 million Series B round in January 2025 led by Balderton Capital, bringing its total funding past $80 million. Lindus Health has delivered more than 42 clinical trials enrolling over 36,000 patients across North America and Europe, and counts MIT professor and Moderna co-founder Robert Langer among its scientific advisors. The company operates its own community and virtual site networks alongside access to more than 30 million electronic health records for patient recruitment.

MAC Clinical Research

MAC Clinical Research operates a network of dedicated research sites across the UK, including facilities in Blackpool, Manchester, Leeds, Liverpool, Cannock, Barnsley, and Stockton-on-Tees, with roots dating to 1988 as one of Europe's first memory assessment centers. The company describes itself as the UK's largest neuroscience research company, maintaining a clear focus on neuropsychiatric disorders, neurodegenerative diseases, inflammation, and pain while also running an MHRA-accredited Phase 1 unit for first-in-human studies. MAC has completed more than 200 studies across Phase I–IV and operates a proprietary patient recruitment and engagement software suite integrated with its site systems to pre-screen and monitor trial participants. The company remains active in local memory assessment services in Blackpool and Leeds, maintaining ties to its original clinical focus even as it has expanded into a broader range of therapeutic areas.

Richmond Pharmacology

Richmond Pharmacology made medical history in November 2020 when it became the first clinical research organization to administer a systemically delivered CRISPR-Cas9 gene-editing therapy to a human patient, working with Intellia Therapeutics on a treatment for ATTR amyloidosis. Founded in 2001 and now operating from a facility on the site of Guy's Hospital in London, the company has since positioned itself as the global leader in in-vivo gene-editing and base-editing clinical trials, having dosed more patients in first-in-human gene-editing studies than any other clinic worldwide. CEO Dr. Jorg Taubel has led the company through a decade-long collaboration with the National Amyloidosis Centre that has made Richmond the largest recruiter for gene-editing trials like Intellia's NTLA-2001. In March 2024, Richmond Pharmacology dosed the first patient in the world's largest Phase 3 CRISPR-Cas9 trial to date.

Simbec-Orion

Simbec-Orion was formed in 2014 through the merger of Simbec Research, a Phase 1 specialist founded in 1976, with Orion Clinical Services, a late-stage development CRO, creating a combined organization with specialist expertise in clinical pharmacology, oncology, and rare and orphan diseases. Headquartered in Merthyr Tydfil, South Wales, the company operates a purpose-built, MHRA-accredited Clinical Pharmacology Unit with 58 beds alongside its own central laboratories, and maintains additional offices across London, Paris, Cologne, Rome, and Princeton, New Jersey. In June 2026, Simbec-Orion was acquired by Caidya, following earlier investment from Altasciences, Arix Capital Management, and CBPE Capital. The company's rare disease and oncology work has been led by CEO Fabrice Chartier, supporting roughly 90 concurrent clinical trials for its client base of large and mid-cap pharmaceutical and biotech companies.

The Medicines Evaluation Unit (MEU)

The Medicines Evaluation Unit (MEU) operates a hospital-based Phase 1 facility in Wythenshawe, Manchester, part of the Manchester University NHS Foundation Trust campus, with 36 inpatient beds equipped with cardiac and telemetry monitoring. The company specializes in Single and Multiple Ascending Dose (SAD/MAD) studies and has particular depth in respiratory and inflammatory disease research, including asthma, COPD, and cystic fibrosis trials, drawing on a volunteer database that passed 35,000 registrants. MEU has held MHRA Phase 1 accreditation continuously since 2009 across seven inspections without a critical or major finding. In 2025, IQVIA made a strategic investment in MEU and its sister company CRO Solutions, giving the global CRO a Phase 1 MHRA-accredited entry point in the UK and plans to grow the Wythenshawe site further under CEO David Rogers' continued leadership.

Explore the full Investigator Site landscape

The companies above represent a portion of a much larger field.

Diligent's platform includes over 280 Investigator Site Vendors, with Vendor qualification data available on demand. Book a demo to see the vendors and qualification reports available on the platform.

This article is intended as an informational overview of vendors operating in this space. Inclusion on this list does not constitute an endorsement, recommendation, or qualification by Diligent.